Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 110, Issue 12, Pages 2896-2904
Publisher
Springer Nature
Online
2014-05-23
DOI
10.1038/bjc.2014.254
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lipid-functionalized Dextran Nanosystems to Overcome Multidrug Resistance in Cancer: A Pilot Study
- (2012) Eisuke Kobayashi et al. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
- Synthesis and Evaluation of (2-(4-Methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) Isomers To Reverse Multidrug Resistance in Cancer
- (2012) Zhenfeng Duan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of curcumin, a component of golden spice, and its miraculous biological activities
- (2011) Subash C Gupta et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters
- (2011) S. Shukla et al. CURRENT DRUG TARGETS
- P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808
- (2010) J. E. Kolitz et al. BLOOD
- Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway
- (2010) Keinosuke Ryu et al. BMC CANCER
- High Wnt Signaling Represses the Proapoptotic Proteoglycan syndecan-2 in Osteosarcoma Cells
- (2010) F.-X. Dieudonne et al. CANCER RESEARCH
- A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
- (2010) R. J. Kelly et al. CLINICAL CANCER RESEARCH
- Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: A report from the Children's Oncology Group
- (2010) Maureen M. O'Brien et al. PEDIATRIC BLOOD & CANCER
- Inhibition of ABCB1 (MDR1) Expression by an siRNA Nanoparticulate Delivery System to Overcome Drug Resistance in Osteosarcoma
- (2010) Michiro Susa et al. PLoS One
- NSC23925, Identified in a High-Throughput Cell-Based Screen, Reverses Multidrug Resistance
- (2009) Zhenfeng Duan et al. PLoS One
- Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines
- (2008) Zhenfeng Duan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase III Study of Valspodar (PSC 833) Combined With Paclitaxel and Carboplatin Compared With Paclitaxel and Carboplatin Alone in Patients With Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or Primary Peritoneal Cancer
- (2008) Catherine Lhommé et al. JOURNAL OF CLINICAL ONCOLOGY
- Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant
- (2008) Amit K. Sharma et al. JOURNAL OF CONTROLLED RELEASE
- Pluronic block copolymers: Evolution of drug delivery concept from inert nanocarriers to biological response modifiers
- (2008) Elena V. Batrakova et al. JOURNAL OF CONTROLLED RELEASE
- Therapy for Osteosarcoma
- (2008) Alexander J Chou et al. PEDIATRIC DRUGS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search